Sistema de Salut de Catalunya
[López-Jiménez T] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Programa de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Plana-Ripoll O] Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. National Center for RegisterBased Research, Aarhus University, Aarhus, Denmark. [Duarte-Salles T] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands. [Palomar-Cros A, Puente D] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain
Departament de Salut
2026-01-27T09:28:55Z
2026-01-27T09:28:55Z
2025-01-16
Cancer; Metabolic syndrome; Remaining life expectancy; Survival
Càncer; Síndrome metabòlica; Esperança de vida restant
Cáncer; Síndrome metabólico; Esperanza de vida restante
This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006-2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.
The project was funded from the Carlos III Institute of Health, (Spain) (reference PI17/00914).
Article
Published version
English
Síndrome metabòlica; Tumors; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance::Metabolic Syndrome; DISEASES::Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperinsulinismo::resistencia a la insulina::síndrome metabólico; ENFERMEDADES::neoplasias; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes
BioMed Central
BMC Public Health;25(1)
https://www.doi.org/10.1186/s12889-025-21437-9
info:eu-repo/grantAgreement/ES/ISCIII/PI17/00914
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by/4.0/
